ImmunityBio Announces Insurance Coverage of ANKTIVA Across Multiple States With First Commercial Doses Administered
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio has announced that its immunotherapy drug ANKTIVA is now covered by multiple insurance plans across several states. The first commercial doses have been administered to patients with BCG unresponsive non-muscle invasive bladder cancer, marking a significant milestone in immunotherapy. ANKTIVA activates the body's immune system to attack resistant tumor cells and has shown a long duration of complete response. Urologists can access more information and support through ImmunityBio CARE™.
June 20, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunityBio's ANKTIVA, a novel immunotherapy for bladder cancer, is now covered by multiple insurance plans and has begun commercial administration. This development is likely to boost the company's revenues and market presence.
The insurance coverage and commercial administration of ANKTIVA are significant milestones for ImmunityBio. This will likely lead to increased adoption and revenue generation, positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100